Logo image of QNCX

QUINCE THERAPEUTICS INC (QNCX) Stock Fundamental Analysis

NASDAQ:QNCX - Nasdaq - US22053A1079 - Common Stock - Currency: USD

1.83  +0.23 (+14.38%)

After market: 1.8 -0.03 (-1.64%)

Fundamental Rating

1

Overall QNCX gets a fundamental rating of 1 out of 10. We evaluated QNCX against 550 industry peers in the Biotechnology industry. QNCX may be in some trouble as it scores bad on both profitability and health. QNCX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year QNCX has reported negative net income.
In the past year QNCX has reported a negative cash flow from operations.
QNCX had negative earnings in each of the past 5 years.
In the past 5 years QNCX always reported negative operating cash flow.
QNCX Yearly Net Income VS EBIT VS OCF VS FCFQNCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

QNCX has a Return On Assets (-56.69%) which is in line with its industry peers.
The Return On Equity of QNCX (-326.73%) is worse than 73.82% of its industry peers.
Industry RankSector Rank
ROA -56.69%
ROE -326.73%
ROIC N/A
ROA(3y)-39.35%
ROA(5y)-45.23%
ROE(3y)-92.25%
ROE(5y)-79.44%
ROIC(3y)N/A
ROIC(5y)N/A
QNCX Yearly ROA, ROE, ROICQNCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for QNCX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QNCX Yearly Profit, Operating, Gross MarginsQNCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for QNCX has been increased compared to 1 year ago.
The number of shares outstanding for QNCX has been increased compared to 5 years ago.
The debt/assets ratio for QNCX is higher compared to a year ago.
QNCX Yearly Shares OutstandingQNCX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
QNCX Yearly Total Debt VS Total AssetsQNCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

QNCX has an Altman-Z score of -5.68. This is a bad value and indicates that QNCX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of QNCX (-5.68) is worse than 62.36% of its industry peers.
QNCX has a Debt/Equity ratio of 0.82. This is a neutral value indicating QNCX is somewhat dependend on debt financing.
The Debt to Equity ratio of QNCX (0.82) is worse than 76.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Altman-Z -5.68
ROIC/WACCN/A
WACCN/A
QNCX Yearly LT Debt VS Equity VS FCFQNCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 4.05 indicates that QNCX has no problem at all paying its short term obligations.
QNCX's Current ratio of 4.05 is in line compared to the rest of the industry. QNCX outperforms 47.09% of its industry peers.
A Quick Ratio of 4.05 indicates that QNCX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.05, QNCX is in line with its industry, outperforming 49.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.05
Quick Ratio 4.05
QNCX Yearly Current Assets VS Current LiabilitesQNCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for QNCX have decreased strongly by -82.53% in the last year.
EPS 1Y (TTM)-82.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

QNCX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.34% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y19.33%
EPS Next 2Y19.77%
EPS Next 3Y15.7%
EPS Next 5Y20.34%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QNCX Yearly Revenue VS EstimatesQNCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M
QNCX Yearly EPS VS EstimatesQNCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QNCX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QNCX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QNCX Price Earnings VS Forward Price EarningsQNCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QNCX Per share dataQNCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

QNCX's earnings are expected to grow with 15.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.77%
EPS Next 3Y15.7%

More info and screens

0

5. Dividend

5.1 Amount

QNCX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUINCE THERAPEUTICS INC

NASDAQ:QNCX (8/12/2025, 8:12:32 PM)

After market: 1.8 -0.03 (-1.64%)

1.83

+0.23 (+14.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners20.5%
Inst Owner ChangeN/A
Ins Owners13.14%
Ins Owner Change5.04%
Market Cap83.21M
Analysts83.64
Price Target7.55 (312.57%)
Short Float %1.88%
Short Ratio2.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-51.69%
Min EPS beat(2)-56.86%
Max EPS beat(2)-46.52%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.07%
PT rev (3m)2.07%
EPS NQ rev (1m)2.31%
EPS NQ rev (3m)-11.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-23.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.48
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.4
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0
BVpS0.41
TBVpS-0.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.69%
ROE -326.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.35%
ROA(5y)-45.23%
ROE(3y)-92.25%
ROE(5y)-79.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 205.62%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.05
Quick Ratio 4.05
Altman-Z -5.68
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)84.29%
Cap/Depr(5y)64.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-82.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.77%
EPS Next Y19.33%
EPS Next 2Y19.77%
EPS Next 3Y15.7%
EPS Next 5Y20.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.18%
OCF growth 3YN/A
OCF growth 5YN/A